European Medicines Agency

London, 24 February 2006
CHMP/71254/2006

PUBLIC STATEMENT ON

THERYTTREX (Yttrium(^{90}Y) Chloride)

WITHDRAWAL OF THE MARKETING AUTHORISATION IN THE EUROPEAN UNION

On 7 January 2003 the European Commission issued a Marketing Authorisation valid throughout the European Union for the medicinal product Theryttrex radiopharmaceutical precursor, solution, intended for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide. This decision was based on the assessment report and on the favourable opinion adopted by the Committee for Proprietary Medicinal Products (CPMP) on 19 September 2002. The Marketing Authorisation Holder responsible for this medicinal product is MDS Nordion S.A., Belgium.

Theryttrex was authorised "to be used only for the radiolabelling of carrier molecules, which have been specifically developed and authorised for radiolabelling with this radionuclide. **Radiopharmaceutical precursor – Not intended for direct use in patients**", only by specialists with the appropriate experience.

Theryttrex has not been marketed anywhere in the EU. On 22 November 2005, MDS Nordion S.A. notified the European Commission of its decision to withdraw the Community Marketing Authorisation for Theryttrex for commercial reasons.

On 2 February 2006, the European Commission issued a decision to withdraw the Marketing Authorisation for Theryttrex. Consequently, the European Public Assessment Report for Theryttrex has been removed from the EMEA website.

Noël Wathion
Head of Unit for the Post-Authorisation Evaluation
of Medicinal Products for Human use

7 Westferry Circus, Canary Wharf, London E14 4HB, UK
Tel. (44-20) 74 18 84 00 Fax (44-20) 74 18 86 68
E-mail: mail@emea.eu.int http://www.emea.eu.int